(+)-VINCRISTINE
Primary Peritoneal Serous Adenocarcinoma
National Cancer Institute (NCI)Small moleculePhase 3Active
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 63/ 100
- Competitive Position
- 89/ 100
Competitive context
13 Active assets in the Primary Peritoneal Serous Adenocarcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan National Cancer Institute (NCI) | Phase 3 | BBB |
Carboplatin National Cancer Institute (NCI) | Phase 3 | BBB |
Olaparib NRG Oncology | Phase 3 | BB |
Cediranib National Cancer Institute (NCI) | Phase 2/3 | BB |
Inno-206 National Cancer Institute (NCI) | Phase 2/3 | BB |
View all 24 →
Same molecule, other indications
(+)-VINCRISTINE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →